AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer...

Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced...

IDEAYA Biosciences announces US FDA IND-clearance for IDE849, a potential first-in-class DLL3 TOP1 ADC, for...

ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement...

VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program

Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting...